Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M Posted byZacks Equity Research February 3, 2022 Leave a comment on Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.